N/A
N=170
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
Arthritis, Rheumatoid
Bottom Line
View on ClinicalTrials.gov: NCT03073109 ↗Enrolled (actual)
170
Serious AEs
0.6%
Results posted
Oct 2020
Primary outcome: Primary: Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Month 6 — 7.12; 5.95; 5.88; 5.94 units on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Month 6 |
7.12; 5.95; 5.88; 5.94; -0.20; -0.32 | — |
| SECONDARY Adapted Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6 |
0.93; 0.77; 0.96; 0.78 | — |
| SECONDARY Change From Baseline in Adapted Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6 |
1.63; 1.50; 1.62; 1.46; -0.56; -0.50 | — |
| SECONDARY European Quality of Life- 5 Dimension-3 Levels (EQ-5D-3L) Index Score at Month 6 |
0.54; 0.67; 0.63; 0.65 | — |
| SECONDARY Change From Baseline in European Quality of Life- 5 Dimension-3 Levels (EQ-5D-3L) Index Score at Month 6 |
0.19; 0.23; 0.30; 0.22; 0.23; 0.29 | — |
| SECONDARY Work Productivity and Activity Impairment Questionnaire for Rheumatoid Arthritis (WPAI:RA) Scores at Month 6 |
12.3; 10.8; 8.78; 10.8; 32.10; 27.7 | — |
| SECONDARY Change From Baseline in Work Productivity and Activity Impairment Questionnaire for Rheumatoid Arthritis (WPAI:RA) Scores at Month 6 |
35.20; 36.10; 31.49; 36.10; -18.4; -19.4 | — |
| SECONDARY Disease Activity Score Based on 28-joints Count (DAS28) at Month 6 |
3.02; 2.61; 3.10; 2.88 | — |
| SECONDARY Change From Baseline in Disease Activity Score Based on 28-joints Count (DAS28) at Month 6 |
5.59; 5.21; 5.21; 5.88; -3.86; -4.23 | — |
| SECONDARY Number of Participants With Serious Adverse Event (SAE) and Non-serious Adverse Events (AEs) |
1; 0; 20; 16 | — |
| SECONDARY Number of Participants With Serious Infections |
1; 0 | — |
| SECONDARY Number of Participants Who Withdrew From Study Due to Adverse Events And Due to All Causes |
0; 1; 10; 2 | — |
Summary
This study is aimed to describe the outcomes related to physical activity, activity of disease, quality of life, work productivity and safety in Latin-American patients with Rheumatoid Arthritis (RA) treated with tofacitinib or biological DMARDs after failure to respond to conventional DMARDs in real-life conditions. This will be a non-interventional, hybrid study (prospective and retrospective data collection) comparing tofacitinib to biologic DMARD treatments in patients with RA after failure of conventional DMARDs. The population will be composed by adult patients over 18 years of age diagnosed with RA and who have been prescribed tofacitinib or any biological DMARDs.
Eligibility Criteria
Inclusion Criteria
- Patients ≥ 18 years of age at the time of recruitment
- Patient diagnosed with moderate to severe RA ≥ 6 months before enrollment
- Patients who have had an inadequate response to the continuous use of methotrexate or combination of conventional DMARDs for at least 12 weeks before the study without dose change within the last 8 weeks before enrollment in the study
- Patients with no biological DMARDs use in patient history.
- Patients prescribed with tofacitinib or biological DMARDs in the last two weeks at doses established in ACR guidelines published in 2015 and following medical criteria.
- Acceptance for patients to participate in the study and signing of the informed consent.
Exclusion Criteria
- Patients who do not have the ability to answer the questionnaires by themselves or who have any kind of mental disorder that may affect their answers.
- Patients diagnosed with autoimmune rheumatic diseases other than RA and Sjogren's syndrome.
- Patients treated with biological DMARDs in monotherapy.
- Participation in other studies involving investigational drug(s) (Phases 1-4) within 4 weeks or 5 half-lives (whichever is longer) after discontinuation of the investigational compound before the current study begins and/or during study participation.
- Patients with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- Patients with lymphoproliferative disorders (e.g., Epstein Barr Virus (EBV) related lymphoproliferative disorder), a history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.
Data sourced from ClinicalTrials.gov (NCT03073109). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.